Comparison of outcomes of HCT in blast phase of BCR-ABL1(-) MPN with de novo AML and with AML following MDS
AuthorGupta, V; Kim, S; Hu, Z-H; Liu, Y; Aljurf, M; Bacher, U; Beitinjaneh, A; Cahn, J-Y; Cerny, J; Copelan, E; ...
Source TitleBlood Advances
PublisherAMER SOC HEMATOLOGY
University of Melbourne Author/sSzer, Jeffrey
AffiliationMedicine and Radiology
Document TypeJournal Article
CitationsGupta, V., Kim, S., Hu, Z. -H., Liu, Y., Aljurf, M., Bacher, U., Beitinjaneh, A., Cahn, J. -Y., Cerny, J., Copelan, E., Gadalla, S. M., Gale, R. P., Ganguly, S., George, B., Gerds, A. T., Gergis, U., Hamilton, B. K., Hashmi, S., Hildebrandt, G. C. ,... Saber, W. (2020). Comparison of outcomes of HCT in blast phase of BCR-ABL1(-) MPN with de novo AML and with AML following MDS. BLOOD ADVANCES, 4 (19), pp.4748-4757. https://doi.org/10.1182/bloodadvances.2020002621.
Access StatusAccess this item via the Open Access location
Open Access URLhttp://doi.org/10.1182/bloodadvances.2020002621
Comparative outcomes of allogeneic hematopoietic cell transplantation (HCT) for BCR-ABL1- myeloproliferative neoplasms (MPNs) in blast phase (MPN-BP) vs de novo acute myeloid leukemia (AML), and AML with prior myelodysplastic syndromes (MDSs; post-MDS AML), are unknown. Using the Center for International Blood and Marrow Transplant Research (CIBMTR) database, we compared HCT outcomes in 177 MPN-BP patients with 4749 patients with de novo AML, and 1104 patients with post-MDS AML, using multivariate regression analysis in 2 separate comparisons. In a multivariate Cox model, no difference in overall survival (OS) or relapse was observed in patients with MPN-BP vs de novo AML with active leukemia at HCT. Patients with MPN-BP in remission had inferior OS in comparison with de novo AML in remission (hazard ratio [HR], 1.40 [95% confidence interval [CI], 1.12-1.76]) due to higher relapse rate (HR, 2.18 [95% CI, 1.69-2.80]). MPN-BP patients had inferior OS (HR, 1.19 [95% CI, 1.00-1.43]) and increased relapse (HR, 1.60 [95% CI, 1.31-1.96]) compared with post-MDS AML. Poor-risk cytogenetics were associated with increased relapse in both comparisons. Peripheral blood grafts were associated with decreased relapse in MPN-BP and post-MDS AML (HR, 0.70 [95% CI, 0.57-0.86]). Nonrelapse mortality (NRM) was similar between MPN-BP vs de novo AML, and MPN-BP vs post-MDS AML. Total-body irradiation-based myeloablative conditioning was associated with higher NRM in both comparisons. Survival of MPN-BP after HCT is inferior to de novo AML in remission and post-MDS AML due to increased relapse. Relapse-prevention strategies are required to optimize HCT outcomes in MPN-BP.
- Click on "Export Reference in RIS Format" and choose "open with... Endnote".
- Click on "Export Reference in RIS Format". Login to Refworks, go to References => Import References